Intercept, Annovis and Biohaven Advance Late Phase Trials

Several biopharma companies reported late-stage Phase III clinical trial success Thursday. Here’s a look.

Positive Pivotal NASH Data Sets Intercept Up for NDA Resubmission

Intercept Pharmaceuticals reported positive topline results from a new interim analysis of its ongoing pivotal Phase III REGENERATE trial. The study is evaluating obeticholic acid (OCA) in liver fibrosis (scarring) due to nonalcoholic steatohepatitis (NASH). NASH is similar to cirrhosis of the liver but occurs in people who drink little or no alcohol. It is a kind of fatty liver disease.